myTomorrows is a global health tech company dedicated to breaking down barriers for patients seeking treatment options.
We strive to enable earlier and better treatment access by bridging the gap between those searching for possible options, and the companies who develop them. We work closely with patients, healthcare professionals, trial sites, patient advocacy groups, and BioPharma – connecting key stakeholders in the drug development ecosystem.
We’ve developed a cutting‑edge AI‑powered technology platform that simplifies and streamlines access to drugs in development. To support our users and clients, we have a range of industry‑expert specialized teams ready to help. Our services include clinical trial patient recruitment, Expanded Access Program management and Real‑World Data collection.
With a global footprint spanning 134 countries, to date we’ve supported over 17,000 patients, 3,000 physicians and 350 sites, earning the trust of 60+ BioPharma companies. In October 2025, we closed a €25M investment with Avego Healthcare Capital to fuel our global ambitions and scale the business.
Join us in shaping the future of treatment access – making tomorrow’s therapies accessible for people who need them today.
The Opportunity: Director, Global AccessReporting to the CEO, and part of myTomorrows’ Extended Leadership Team (XLT), the Director Global Access is responsible for shaping and executing global access strategies that enable compliant, sustainable patient access across international markets, from expanded access through post‑marketing authorization transition.
This strategic role sits at the intersection of Global Access, Market Access, and post Marketing Authorization (MA) readiness, ensuring that Paid‑for Expanded Access Programs (EAPs) and Named Patient Programs (NPPs) are strategically aligned with local reimbursement pathways, health system requirements, and future commercial access, while remaining strictly non‑promotional.
The Director owns the post‑signature access enablement layer, including field infrastructure, (sub)distributor governance, and medical field capabilities, and plays a key role in preparing the organization for post‑MA activities by building scalable access capabilities, governance models, and cross‑functional ways of working that support transition to approved use. The role partners closely with the broader Commercial organization, EAP Operations and Legal & Compliance to ensure ethical, regulatory‑compliant execution. Where appropriate, you and your team will also engage with external access stakeholders such as governments, payors, and healthcare system bodies to support aligned and compliant access pathways.
The role does not own EAP operational delivery, but is accountable for access performance, sustainability, and strategic alignment across markets.
What you’ll do in this role: Strategic accountabilitiesDefine and evolve global access and post‑MA readiness strategies across the portfolio, aligned with corporate priorities, partner objectives, and regulatory constraints.
Set access prioritization and market sequencing strategy based on access feasibility, health system readiness, risk profile, and long‑term sustainability.
Shape target access models by market, including expanded access‑only, transitional access, and post‑MA handover models, and define the strategic principles governing each.
Design the access‑related capabilities, governance structures, and operating models required to prepare the organization for post‑MA activities.
Establish clear decision frameworks for transitioning programs from expanded access to post‑MA environments, including role boundaries, handover points, and risk ownership.
Advise the CEO on access‑related risks, trade‑offs, and investment priorities, informed by ongoing monitoring of global policy, reimbursement, and expanded access trends.
Together with the Pharma Partnerships team, shape the strategic access value proposition for pharma partners, positioning Global Access programs as part of a broader, compliant access and post‑MA journey
Enable and be accountable for program performance, access outcomes, and sustainability across assigned regions, in line with Global Access strategy.
Translate global access and post‑MA readiness strategies into locally appropriate, compliant execution models.
Own the post‑signature access enablement layer, including field infrastructure, (sub)distributor governance, and medical field capabilities.
Build, onboard, and oversee (sub)distributor networks supporting paid‑for and free‑of‑charge EAPs, with robust governance, training, and audit‑ready oversight.
Build and scale local, high‑performing Medical Science Liaison teams to deliver high‑quality, non‑promotional medical‑scientific support, ensuring clear separation from commercial and performance‑driven activities.
Partner closely with EAP Operations, Legal, Compliance, and Commercial stakeholders to ensure aligned, ethical, and regulatory‑compliant execution.
Engage, where appropriate and within approved governance frameworks, with governments, payors, and healthcare system stakeholders to support aligned and compliant access pathways.
Identify, assess, and mitigate execution‑ and transition‑related risks across markets, partners, and field teams.
Post‑signature delivery and post‑MA readiness.
Ensure accurate forecasting, CRM tracking (HubSpot), performance monitoring, and structured reporting.
Partner with the Pharma Partnerships team during pre‑signature discussions to shape realistic, compliant global access approaches, assess execution feasibility, and set clear expectations for post‑signature delivery and post‑MA readiness.
Support audits, inspections, and partner reviews related to access execution and readiness
You have developed a clear understanding of the Global Access portfolio, regional priorities, and the regulatory boundaries governing EAPs.
Roles, responsibilities, interfaces, and decision rights between Global Access Execution, EAP Operations, Medical, Quality, Compliance, and Commercial stakeholders are clearly understood and respected.
A baseline execution and governance framework is in place for distributors and field teams, including training requirements, escalation pathways, and documentation standards, informed by longer‑term scalability and post‑MA readiness considerations.
Strategic plans including priority markets are defined across the portfolio, based on strategic access potential, feasibility, and risk profile, and due diligence has started on potential (sub)distributor partners.
You are recognized internally as a trusted, compliance‑minded leader who combines strategic access thinking with strong execution discipline.
A clear, compliant access execution model is established and operational in priority markets, with well‑defined boundaries between access enablement, EAP operational responsibilities, and post‑MA considerations.
Approved global access and post‑MA readiness strategies are actively guiding execution decisions, market sequencing, and resource allocation across regions.
Priority (sub)distributors are onboarded with strong governance, training, and oversight mechanisms, aligned with both immediate execution needs and longer‑term scalability.
Local MSL capability is in place in priority markets, operating fully within regulatory and medical standards and supporting medical readiness for post‑MA activities.
Program performance and access‑related revenue outcomes are achieved without compliance findings or audit issues.
You are trusted internally and by partners as a leader who enables access responsibly, balances strategic intent with operational discipline, and protects patient and company interests.
A stable, scalable, and audit‑ready global access and post‑MA enablement structure is operating across multiple geographies, aligned with the organization’s long‑term access and growth strategy.
Distributor and MSL models are mature, well‑governed, and consistently compliant with global and local requirements, and are designed to support sustained access and transition toward post‑MA activities.
Execution and access insights are systematically informing program expansions, renewals, sales positioning, and the evolution of future Global Access and post‑MA strategies.
The Global Access function is viewed internally and externally as a strategic and operational benchmark for compliant access enablement.
Pharma partners demonstrate high confidence in myTomorrows’ ability to support responsible, sustainable access from early access through post‑MA transition.
Trusted, compliant engagement models with governments, payors, and healthcare system stakeholders are established and embedded, supporting sustainable access pathways over time.
myTomorrows is an Equal Opportunity Employer and, beyond upholding discrimination‑free practices, we are committed to cultivating a workplace where difference and diversity are protected and celebrated. The best work comes from our best selves, and we go to great lengths in supporting our team members to be just that.
#J-18808-Ljbffr€90000 - €130000 monthly